Becton, Dickinson and (BDX) Q4 FY2026 Earnings Call: Q&A Summary

Q: Patrick Andrew Wood from UBS asked how management thinks about the rate of investment to drive top-line growth relative to margins.

A: Thomas Polen (Chairman, Chief Executive Officer and President) and Vitor Roque (Executive Vice President and Chief Financial Officer) answered that investments in advanced patient monitoring, peripheral intervention, and urology are yielding double-digit growth and accretive margins, and that these growth drivers will continue to fuel operating margin expansion despite inflationary environments.

Q: Travis Steed from Bank of America asked about the guidance philosophy and the factors behind the lower Q1 outlook.

A: Vitor Roque (CFO) and Thomas Polen (CEO) explained that the guidance approach remains responsible and prudent, and that Q1 is impacted by a more acute Alaris headwind of about 250 basis points and a conservative assumption regarding the APM system integration cutover.

Q: Vijay Kumar from Evercore ISI asked why fiscal 2027 growth is guided at 2% to 2.5% given strong back-half performance in fiscal 2026.

A: Vitor Roque (CFO) and Thomas Polen (CEO) responded that management takes a prudent approach to forecasting and accounts for a 200 basis point headwind from Alaris with a more acute impact in the first half.

Q: Robert Marcus from JPMorgan asked about U.S. health care utilization, political impacts, and international trends including China and Europe.

A: Thomas Polen (CEO) stated that U.S. utilization remains strong, capital spending is selective but robust in areas like pharmacy automation and APM, China is stable and a smaller portion of the business, and Europe is showing strong performance particularly in pharmacy automation.

Q: Matthew Taylor from Jefferies asked for insight into the Section 232 tariffs and how tariff relief is contemplated in fiscal 2027 guidance.

A: Thomas Polen (CEO) answered that fiscal 2027 guidance assumes tariffs generally in line with fiscal 2026 and includes no benefit from the government partnership yet because the 232 product scope and timing are not finalized, representing a potential upside.

Q: Larry Biegelsen from Wells Fargo asked for a preview of the upcoming Analyst Day and whether mid-single-digit growth and P&L leverage are expected once Alaris rolls over.

A: Thomas Polen (CEO) confirmed that the company expects to return to mid-single-digit growth and solid margin expansion once the Alaris headwind goes away, and that Investor Day will provide strategic updates, innovation highlights, and long-term financial targets.

Q: Joshua Jennings from TD Cowen asked about the durability of growth for the Biologics and GLP-1 franchise.

A: Thomas Polen (CEO) responded that the company expects continued strong performance driven by high win rates, novel molecules, biosimilars expansion such as in Brazil, and added that vaccine headwinds are expected to dissipate in fiscal 2027.

Q: Joanne Wuensch from Citibank asked to tease out the components of flat fiscal 2027 operating margins and requested a view on artificial intelligence applications.

A: Vitor Roque (CFO) and Thomas Polen (CEO) stated that gross and operating margins are expected to be similarly flat due to inflation and continued strategic investments, and detailed AI applications across products like Ankata, manufacturing via the Cognite platform, and commercial sales tools.

Q: Michael Polark from Wolfe Research asked how to square BD's optimism on GLP-1s with a competitor's cautious outlook on glass packaging for GLP-1s in 2027.

A: Thomas Polen (CEO) declined to comment on specific competitors and reiterated that BD's high win rates for new molecules and biosimilars support continued solid growth in GLP-1s.

Q: Chris Pascal from Barclays asked about capital allocation priorities in fiscal 2027 regarding debt paydown, share buybacks, and M&A.

A: Vitor Roque (CFO) answered that share buybacks and dividends remain a top priority alongside debt paydown to achieve target net leverage, while maintaining financial flexibility for focused tuck-in M&A.